In addition to making it the latest biotech unicorn, Mammoth Biosciences, Inc. ’s most recent venture capital funding round will also help catapult the company further into CRISPR-based therapeutics, in addition to its more publicized efforts to develop CRISPR-based diagnostics. The company’s particular focus is on ultra-small CRISPR systems that open up more possibilities for delivery options, such as CRISPR/Cas14 and CRISPR/Casφ.
The Brisbane, CA-based company said on 9 September that it raised $150m in a series D funding round, plus $45m in a series C round in late 2020, bringing its valuation to more than $1bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?